Aswani Babu Santha Aswani

Ms. Aswani Babu Santha Aswani


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ASAnjana Sajeev
Anjana Sajeev
AAAswani Babu Santha Aswani
Aswani Babu Santha Aswani
MAMohammed Alqahtani
Mohammed Alqahtani
MAMohamed Abbas
Mohamed Abbas
Gautam SethiGautam Sethi
Gautam Sethi
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Background/Objectives: The integration of natural compounds in cancer research marked a crucial shift in the modern medical landscape, through a growing acknowledgment of their potential as efficient, less toxic, and cost-effective alternatives to contemporary chemotherapeutics. Liquiritigenin (LIQ) is a compound obtained from different plants, the most important being the Glycyrrhiza species, commonly known as licorice. Methods: This review compiles findings from previously published preclinical studies and experimental research articles focusing on LIQ’s pharmacological effects, with particular attention to its anticancer potential. The relevant literature was identified using established scientific databases and selected based on relevance to cancer biology and LIQ-associated signaling pathways. Results: LIQ demonstrates anti-oxidant, anti-inflammatory, and anti-proliferative effects. It exerts its potential anticancer activities by inducing apoptosis, preventing cell proliferation, and modulating various signaling pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), and so on. Conclusions: LIQ represents a promising natural agent for cancer therapy, with evidence supporting its multifunctional role in targeting tumor growth and survival mechanisms. By providing a detailed analysis of LIQ, this review aims to highlight its therapeutic efficacy across various cancer types and emphasize its importance as a promising compound in cancer research. In addition, this review seeks to bridge the gap between traditional medicine and modern pharmacology and paves the way for LIQ’s clinical application in cancer therapy.

22 March 2024 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
ASAnjana Sajeev
Anjana Sajeev
RVRavichandran Vishwa
Ravichandran Vishwa
AAAswani Babu Santha Aswani
Aswani Babu Santha Aswani
MAMohammed Alqahtani
Mohammed Alqahtani
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara

9 February 2024 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
MKM MUKESH KUMAR
M MUKESH KUMAR
ASAnjana Sajeev
Anjana Sajeev
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
MAMohammed Alqahtani
Mohammed Alqahtani
MAMohamed Abbas
Mohamed Abbas
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Hematological malignancies (HM) represent a subset of neoplasms affecting the blood, bone marrow, and lymphatic systems, categorized primarily into leukemia, lymphoma, and multiple myeloma. Their prognosis varies considerably, with a frequent risk of relapse despite ongoing treatments. While contemporary therapeutic strategies have extended overall patient survival, they do not offer cures for advanced stages and often lead to challenges such as acquisition of drug resistance, recurrence, and severe side effects. The need for innovative therapeutic targets is vital to elevate both survival rates and patients' quality of life. Recent research has pivoted towards nuclear receptors (NRs) due to their role in modulating tumor cell characteristics including uncontrolled proliferation, differentiation, apoptosis evasion, invasion and migration. Existing evidence emphasizes NRs' critical role in HM. The regulation of NR expression through agonists, antagonists, or selective modulators, contingent upon their levels, offers promising clinical implications in HM management. Moreover, several anticancer agents targeting NRs have been approved by the Food and Drug Administration (FDA). This review highlights the integral function of NRs in HM's pathophysiology and the potential benefits of therapeutically targeting these receptors, suggesting a prospective avenue for more efficient therapeutic interventions against HM. Graphical abstract

9 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NPNath Pampita
Nath Pampita
AAAswani Babu Santha Aswani
Aswani Babu Santha Aswani
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
SLSameena Lone
Sameena Lone
MHMangala Hegde
Mangala Hegde
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Cancer remains one of the most frightening global health challenges, contributing substantially to morbidity and mortality across diverse populations. In recent years, naturally derived compounds have attracted considerable attention due to their potential therapeutic efficacy and fewer adverse effects. Among these, the flavokawain subclass of chalcones, comprising Flavokawains A, B, and C, obtained from various plant sources, has emerged as a promising group of bioactive phytochemicals exhibiting a broad spectrum of pharmacological activities, with notable anticancer potential. This review critically compiles and evaluates the existing preclinical evidence regarding the anticancer mechanisms of flavokawains across various cancer models. It was found that these compounds have significant potential to inhibit cancer cell proliferation, induce apoptosis, disrupt cell-cycle progression, and modulate multiple molecular pathways implicated in tumorigenesis, including phosphoinositide 3 kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), extracellular-signal regulated kinase/c-Jun N-terminal kinase/mitogen-activated protein kinase (ERK/JNK/MAPK) and so on. Importantly, flavokawains exert significant modulatory effects within the tumor microenvironment by suppressing angiogenesis through downregulation of vascular endothelial growth factor (VEGF) and Angiopoietin-1 (Ang-1), attenuating epithelial-mesenchymal transition via restoration of E-cadherin and suppression of vimentin and Snail1, inhibiting matrix metalloproteinase (MMP)-mediated extracellular matrix remodeling, and disrupting cancer stem cell (CSC)-supportive niches. Preclinical toxicity profiles suggest a favorable safety margin, though further investigation is required to fully elucidate their therapeutic index. Due to their multifaceted mechanisms of action and selective cytotoxicity toward cancer cells, flavokawains are considered promising preclinical candidates for development as adjuncts or alternatives to conventional chemotherapeutic agents.